Abstrakt
The mantle cell lymphoma (MCL) International Prognostic Index is widely used as a strong prognostic stratifier, but it has rarely been used for the selection of therapeutic approaches. New molecular prognostic predictors, which would reflect critical aspects of MCL biology and that would help in therapy decisions, have been under investigation.
Recently, several key studies provided evidence of the poor prognostic impact of tumour protein p53 (TP53) gene aberrations or high p53 protein expression in patients with MCL. There is a growing body of evidence that TP53 aberrations could contribute to chemoresistance.
In the present study, we analysed the prognostic impact of the extent of a TP53 gene aberration (TP53 mutation burden and deletion of 17p frequency) in a real-world cohort of patients with MCL.